Sunny C. Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sunny C. Li has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Xiaowei Chen
Brain Research Center and State Key Laboratory of Trauma and Chemical Poisoning, Third Military Medical University, Chongqing, China
5 shared publications Kuan Zhang
Brain Research Center and State Key Laboratory of Trauma and Chemical Poisoning, Third Military Medical University, Chongqing 400038, China
3 shared publications- Zhikai Zhao
Chongqing University, School of Medicine, Center for Neurointelligence, Chongqing, China
3 shared publications Zhiqi Yang
Brain Research Center and State Key Laboratory of Trauma and Chemical Poisoning, Third Military Medical University, Chongqing 400038, China
3 shared publicationsHongbo Jia
Guangxi Key Laboratory of Special Biomedicine/Advanced Institute for Brain and Intelligence, School of Medicine, Guangxi University, Nanning 530004, China; Leibniz Institute for Neurobiology, Magdeburg 39118, Germany; Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou 215163, China
2 shared publicationsJie Tao
Guangxi Key Laboratory of Special Biomedicine/Advanced Institute for Brain and Intelligence, School of Medicine, Guangxi University, Nanning 530004, China
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by SPIE-Intl Soc Optical Eng in Neurophotonics
- Vol. 13 (01) , 1-15
Tonotopic organization in the basal region of the ventromedial nucleus of the thalamus revealed by fiber photometry recording
SignificanceAlthough the transmission of auditory information in the brain has been extensively studied, the mechanism underlying fine auditory discrimination remains incompletely understood. The basal region of the ventromedial nucleus of the thalamus (bVM) has recently been found to convey frequency-specific auditory information to the primary auditory cortex (A1). Inhibition of the bVM significantly impairs fine auditory discrimination in mice. These findings indicate that the bVM plays an important role in frequency information processing. However, direct functional evidence for tonotopic organization within the bVM is still lacking.AimWe aimed to investigate whether bVM neurons exhibit a spatially ordered frequency preference, using a simple yet efficient in vivo functional mapping strategy.ApproachTo characterize the response properties of bVM neurons projecting to A1, we combined Cre-dependent retrograde viral labeling with fiber photometry in awake mice. Using a “one recording site per animal” strategy, we systematically recorded from 26 distinct locations and successfully reconstructed the tonotopic map of the bVM.ResultsWe identified a mediolateral tonotopic gradient within the bVM, with best frequencies progressing from low in medial regions to high in lateral regions.ConclusionsOur findings provide direct functional evidence of tonotopic organization within the bVM, supporting its role as an auditory relay and its contribution to fine auditory discrimination.
- 1 January 2026
- Published by SPIE-Intl Soc Optical Eng in Neurophotonics
- Vol. 13 (01) , 1-15
Open AccessTonotopic organization in the basal region of the ventromedial nucleus of the thalamus revealed by fiber photometry recording
SignificanceAlthough the transmission of auditory information in the brain has been extensively studied, the mechanism underlying fine auditory discrimination remains incompletely understood. The basal region of the ventromedial nucleus of the thalamus (bVM) has recently been found to convey frequency-specific auditory information to the primary auditory cortex (A1). Inhibition of the bVM significantly impairs fine auditory discrimination in mice. These findings indicate that the bVM plays an important role in frequency information processing. However, direct functional evidence for tonotopic organization within the bVM is still lacking.AimWe aimed to investigate whether bVM neurons exhibit a spatially ordered frequency preference, using a simple yet efficient in vivo functional mapping strategy.ApproachTo characterize the response properties of bVM neurons projecting to A1, we combined Cre-dependent retrograde viral labeling with fiber photometry in awake mice. Using a “one recording site per animal” strategy, we systematically recorded from 26 distinct locations and successfully reconstructed the tonotopic map of the bVM.ResultsWe identified a mediolateral tonotopic gradient within the bVM, with best frequencies progressing from low in medial regions to high in lateral regions.ConclusionsOur findings provide direct functional evidence of tonotopic organization within the bVM, supporting its role as an auditory relay and its contribution to fine auditory discrimination.
- Open Access
- 16 June 2025
- Published by Elsevier in Science Bulletin
- Vol. 70 (17) , 2824-2835
Parvalbumin interneurons are essential for tonotopy strength in the auditory cortex
- 16 June 2025
- Published by Elsevier in Science Bulletin
- Vol. 70 (17) , 2824-2835
Open AccessParvalbumin interneurons are essential for tonotopy strength in the auditory cortex
- Open Access
- 29 May 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (6) , 816
Withaferin A Rescues Brain Network Dysfunction and Cognitive Deficits in a Mouse Model of Alzheimer’s Disease
Background: Alzheimer’s disease (AD) is the most common dementia, characterized by significant cognitive impairments and neural network dysfunction. Currently, multiple therapeutic strategies are being developed to design effective anti-AD drugs. Among them, Withaferin A (WA), a natural steroidal lactone extracted from Withania somnifera leaves, has been shown to reduce amyloid-β (Aβ) peptide levels in vitro. However, its potential to improve cognitive function in AD remains unclear. Methods: In this study, 5xFAD mice were administered WA (2 mg/kg intraperitoneally every 2 days) for 14 days, and its neuroprotective effects were evaluated through behavioral tests, wide-field imaging, immunohistochemistry, and ELISA. Results: WA significantly improved short-term memory, as evidenced by enhanced performance in the Novel Object Recognition Test (NORT) (p < 0.001, n = 10), Novel Location Recognition Test (NLRT) (p < 0.01, n = 14), and Three-Chamber Social Test (TCST) (p < 0.001, n = 8). WA also ameliorated long-term memory deficits in the Morris Water Maze Test (MWMT) (p < 0.05, n = 7). Furthermore, cortical wide-field Ca2+ imaging revealed that WA treatment rescued slow-wave impairments by enhancing long-range coherence (0.8363 ± 0.0185, p < 0.01, n = 8) and reducing the frequency of slow-wave activity (0.6578 ± 0.0512 Hz, p < 0.01, n = 8). Additionally, WA treatment significantly reduced Aβ plaque deposition in both cortical and hippocampal regions. Conclusions: These findings suggest that WA may be a promising therapeutic agent for AD, exerting neuroprotective effects.
- 29 May 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (6) , 816
Open AccessWithaferin A Rescues Brain Network Dysfunction and Cognitive Deficits in a Mouse Model of Alzheimer’s Disease
Background: Alzheimer’s disease (AD) is the most common dementia, characterized by significant cognitive impairments and neural network dysfunction. Currently, multiple therapeutic strategies are being developed to design effective anti-AD drugs. Among them, Withaferin A (WA), a natural steroidal lactone extracted from Withania somnifera leaves, has been shown to reduce amyloid-β (Aβ) peptide levels in vitro. However, its potential to improve cognitive function in AD remains unclear. Methods: In this study, 5xFAD mice were administered WA (2 mg/kg intraperitoneally every 2 days) for 14 days, and its neuroprotective effects were evaluated through behavioral tests, wide-field imaging, immunohistochemistry, and ELISA. Results: WA significantly improved short-term memory, as evidenced by enhanced performance in the Novel Object Recognition Test (NORT) (p < 0.001, n = 10), Novel Location Recognition Test (NLRT) (p < 0.01, n = 14), and Three-Chamber Social Test (TCST) (p < 0.001, n = 8). WA also ameliorated long-term memory deficits in the Morris Water Maze Test (MWMT) (p < 0.05, n = 7). Furthermore, cortical wide-field Ca2+ imaging revealed that WA treatment rescued slow-wave impairments by enhancing long-range coherence (0.8363 ± 0.0185, p < 0.01, n = 8) and reducing the frequency of slow-wave activity (0.6578 ± 0.0512 Hz, p < 0.01, n = 8). Additionally, WA treatment significantly reduced Aβ plaque deposition in both cortical and hippocampal regions. Conclusions: These findings suggest that WA may be a promising therapeutic agent for AD, exerting neuroprotective effects.
- Open Access
- 5 April 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1) , 1-15
Pitolisant alleviates brain network dysfunction and cognitive deficits in a mouse model of Alzheimer’s disease
Histamine H3 receptor (H3R) antagonists regulate histamine release that modulates neuronal activity and cognitive function. Although H3R is elevated in Alzheimer’s disease (AD) patients, whether H3R antagonists can rescue AD-associated neural impairments and cognitive deficits remains unknown. Pitolisant is a clinically approved H3R antagonist/inverse agonist that treats narcolepsy. Here, we find that pitolisant reverses AD-like pathophysiology and cognitive impairments in an AD mouse model. Behavioral assays and in vivo wide-field Ca2+ imaging revealed that recognition memory, learning flexibility, and slow-wave impairment were all improved following the 15-day pitolisant treatment. Improved recognition memory was tightly correlated with slow-wave coherence, suggesting slow waves serve as a biomarker for treatment response and for AD drug screening. Furthermore, pitolisant reduced amyloid-β deposition and dystrophic neurites surrounding plaques, and enhanced neuronal lysosomal activity, inhibiting which blocked cognitive and slow-wave restoration. Our findings identify pitolisant as a potential therapeutic agent for AD treatments.
- 5 April 2025
- Published by Springer Nature in Translational Psychiatry
- Vol. 15 (1) , 1-15
Open AccessPitolisant alleviates brain network dysfunction and cognitive deficits in a mouse model of Alzheimer’s disease
Histamine H3 receptor (H3R) antagonists regulate histamine release that modulates neuronal activity and cognitive function. Although H3R is elevated in Alzheimer’s disease (AD) patients, whether H3R antagonists can rescue AD-associated neural impairments and cognitive deficits remains unknown. Pitolisant is a clinically approved H3R antagonist/inverse agonist that treats narcolepsy. Here, we find that pitolisant reverses AD-like pathophysiology and cognitive impairments in an AD mouse model. Behavioral assays and in vivo wide-field Ca2+ imaging revealed that recognition memory, learning flexibility, and slow-wave impairment were all improved following the 15-day pitolisant treatment. Improved recognition memory was tightly correlated with slow-wave coherence, suggesting slow waves serve as a biomarker for treatment response and for AD drug screening. Furthermore, pitolisant reduced amyloid-β deposition and dystrophic neurites surrounding plaques, and enhanced neuronal lysosomal activity, inhibiting which blocked cognitive and slow-wave restoration. Our findings identify pitolisant as a potential therapeutic agent for AD treatments.